文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

中医与肺纤维化相互作用的全球研究现状与趋势:治疗新曙光

Global research status and trends of interactions between Traditional Chinese medicine and pulmonary fibrosis: A new dawn in treatment.

作者信息

Wei Bokai, Li Haozheng, Wang Chengyu, Hu Jing

机构信息

School of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, 1200# Cailun Rd., Shanghai, 201203, PR China.

Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, 130# Dongan Road, Shanghai, 200032, PR China.

出版信息

Heliyon. 2024 Jul 14;10(14):e34592. doi: 10.1016/j.heliyon.2024.e34592. eCollection 2024 Jul 30.


DOI:10.1016/j.heliyon.2024.e34592
PMID:39149021
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11325230/
Abstract

BACKGROUND: Pulmonary fibrosis (PF) remains a major sequela of COVID-19, yet its pharmacotherapy remains unsatisfactory. Recently, Traditional Chinese medicine (TCM) has garnered increasing recognition among patients and researchers because of its few side effects and efficacy. The objective of this study is to use bibliometric analysis to explore the current research landscape and emerging trajectories of TCM treating PF(TCM/PF) researches, and comprehensively evaluate publications with substantial citations within the domain of TCM/PF. MATERIALS AND METHODS: TCM/PF publications from 1996 to June 15, 2023 were identified by a comprehensive search of the Web of Science Core Collection (WoSCC). The Bibliometrix of Origin, CiteSpace, Gephi, dycharts and VOSviewer were used for bibliometric analysis. RESULTS: A total of 358 papers were included. A rapid increase in the number of papers after 2013 was observed. China had the highest publication output and research contributions in this field. Beijing University of Traditional Chinese Medicine and Nanjing University of Traditional Chinese Medicineare leaders in productive research of this field. Nanjing University of Traditional Chinese Medicine had the highest citations (227). LI JIANSHENG from Henan University of Chinese Medicine was the most prolific author (8), with the highest number of citations (61), and TONG XIAO LIN from China Academy of Chinese Medical Sciences had the highest H-index (30). The leading journal publishing the most research (37) is Frontiers in Pharmacology and the Journal of Ethnopharmacology had the highest total citations (486). Burst analysis of keywords revealed three distinct phases of research. 1996 to 2013 marked the nascent stage of TCM/PF research; from 2014 to 2018, studies gradually focused on the underlying mechanisms governing TCM/PF. The most significant phase occurred from 2019 onward, where TCM/PF exhibited an explosive growth trend. This progression signifies a transition from foundational explorations to a comprehensive understanding of the mechanisms involved, ultimately leading to the current surge in research activities focused on TCM/PF. Notable research teams of this stage, led by LI JIAN SHENG and TONG XIAO LIN, have been at the forefront of advancing TCM/PF research. Their studies on Jinshui Huanxian formula and Qimai Feiluoping decoction have been pivotal in advancing the frontier of research in this domain. Furthermore, the monomeric compounds, including emodin, curcumin, salvianolic acid, baicalin, and oxymatrine, have sustained longstanding prominence. CONCLUSIONS: This study gained insight into the research status, focal areas and evolving trends of global TCM/PF research. It also identified the most cited articles in TCM/PF and analyzed their characteristics, which may hold significant relevance for both clinical researchers and practitioners on future directions in this field.

摘要

背景:肺纤维化(PF)仍是新型冠状病毒肺炎(COVID-19)的主要后遗症,但其药物治疗仍不尽人意。近年来,中医药(TCM)因其副作用少且疗效显著,在患者和研究人员中获得了越来越多的认可。本研究旨在通过文献计量分析,探索中医药治疗PF(TCM/PF)研究的现状和新兴趋势,并全面评估TCM/PF领域内被大量引用的文献。 材料与方法:通过全面检索科学网核心合集(WoSCC),确定1996年至2023年6月15日期间的TCM/PF文献。使用Origin的Bibliometrix、CiteSpace、Gephi、dycharts和VOSviewer进行文献计量分析。 结果:共纳入358篇论文。观察到2013年后论文数量迅速增加。中国在该领域的发文量和研究贡献最高。北京中医药大学和南京中医药大学是该领域高产研究的领军者。南京中医药大学的被引次数最高(227次)。河南中医药大学的李建生是发文量最多的作者(8篇),被引次数最高(61次),中国中医科学院的仝小林H指数最高(30)。发表研究最多(37篇)的领先期刊是《药理学前沿》,《民族药理学杂志》的总被引次数最高(486次)。关键词的突现分析揭示了三个不同的研究阶段。1996年至2013年是TCM/PF研究的初期阶段;2014年至2018年,研究逐渐聚焦于TCM/PF的潜在机制。最显著的阶段发生在2019年以后,TCM/PF呈现出爆炸式增长趋势。这一进展标志着从基础探索向对所涉机制的全面理解的转变,最终导致当前聚焦于TCM/PF的研究活动激增。这个阶段的知名研究团队,以李建生和仝小林为首,一直处于推进TCM/PF研究的前沿。他们对金水还仙方和芪麦肺络平汤的研究对推动该领域的研究前沿起到了关键作用。此外,大黄素、姜黄素、丹酚酸、黄芩苷和氧化苦参碱等单体化合物一直备受关注。 结论:本研究深入了解了全球TCM/PF研究的现状、重点领域和发展趋势。它还确定了TCM/PF领域中被引用最多的文章,并分析了它们的特点,这可能对临床研究人员和从业者在该领域的未来方向具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d04a/11325230/71d2c9f5f0d4/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d04a/11325230/41b5c2b747bc/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d04a/11325230/1dfdeb556659/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d04a/11325230/f9746bae275e/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d04a/11325230/d0d9eedbc769/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d04a/11325230/87d4f39fcd34/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d04a/11325230/776457047aef/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d04a/11325230/9184490e3745/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d04a/11325230/71d2c9f5f0d4/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d04a/11325230/41b5c2b747bc/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d04a/11325230/1dfdeb556659/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d04a/11325230/f9746bae275e/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d04a/11325230/d0d9eedbc769/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d04a/11325230/87d4f39fcd34/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d04a/11325230/776457047aef/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d04a/11325230/9184490e3745/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d04a/11325230/71d2c9f5f0d4/gr7.jpg

相似文献

[1]
Global research status and trends of interactions between Traditional Chinese medicine and pulmonary fibrosis: A new dawn in treatment.

Heliyon. 2024-7-14

[2]
The interactions between traditional Chinese medicine and gut microbiota: Global research status and trends.

Front Cell Infect Microbiol. 2022

[3]
Emerging insights into traditional Chinese medicine associated with neurodegenerative diseases: A bibliometric analysis.

J Ethnopharmacol. 2025-1-30

[4]
Bibliometric analysis of traditional Chinese medicine in the treatment of inflammatory bowel disease.

Allergol Immunopathol (Madr). 2024

[5]
Exploring global research trends in Chinese medicine for atherosclerosis: a bibliometric study 2012-2023.

Front Cardiovasc Med. 2024-6-17

[6]
Exploring global research status and trends in anti-obesity effects of traditional Chinese medicine through intestinal microbiota: a bibliometric study.

Front Cell Infect Microbiol. 2023

[7]
Bibliometric analysis of research trends and topic areas in traditional Chinese medicine therapy for lymphoma.

Pharm Biol. 2024-12

[8]
[CiteSpace knowledge map of research hotspots and frontiers of traditional Chinese medicine intervention in psoriasis in recent ten years].

Zhongguo Zhong Yao Za Zhi. 2023-6

[9]
Research trends on traditional Chinese medicine and acute pancreatitis: A bibliometric analysis from 2007 to mid-2023.

Heliyon. 2024-2-15

[10]
Research trends and hotspots of neurodegenerative diseases employing network pharmacology: A bibliometric analysis.

Front Pharmacol. 2023-1-12

引用本文的文献

[1]
Mechanism study of the effects of astragaloside IV and quercetin on idiopathic pulmonary fibrosis.

J Nat Med. 2025-4-30

本文引用的文献

[1]
Pharmacological effects of baicalin in lung diseases.

Front Pharmacol. 2023-4-24

[2]
Oxymatrine inhibits TGF‑β1‑mediated mitochondrial apoptotic signaling in alveolar epithelial cells via activation of PI3K/AKT signaling.

Exp Ther Med. 2023-3-20

[3]
Qimai Feiluoping decoction inhibits mitochondrial complex I-mediated oxidative stress to ameliorate bleomycin-induced pulmonary fibrosis.

Phytomedicine. 2023-4

[4]
Monomeric compounds from traditional Chinese medicine: New hopes for drug discovery in pulmonary fibrosis.

Biomed Pharmacother. 2023-3

[5]
Effective-compounds of Jinshui Huanxian formula ameliorates fibroblast activation in pulmonary fibrosis by inhibiting the activation of mTOR signaling.

Phytomedicine. 2023-1

[6]
Yangqing Chenfei formula attenuates silica-induced pulmonary fibrosis by suppressing activation of fibroblast via regulating PI3K/AKT, JAK/STAT, and Wnt signaling pathway.

Phytomedicine. 2023-2

[7]
Progressive pulmonary fibrosis: an expert group consensus statement.

Eur Respir J. 2023-3

[8]
Emodin inhibiting epithelial-mesenchymal transition in pulmonary fibrosis through the c-MYC/miR-182-5p/ZEB2 axis.

Phytother Res. 2023-3

[9]
PEAR1 regulates expansion of activated fibroblasts and deposition of extracellular matrix in pulmonary fibrosis.

Nat Commun. 2022-11-19

[10]
Efficacy and safety of traditional Chinese medicine treatment for idiopathic pulmonary fibrosis: An exploratory, randomized, double-blinded and placebo controlled trial.

Front Pharmacol. 2022-10-28

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索